272 Correlations of inflammatory biomarkers with endoscopic disease activity in IBD Endoscopic examination of 71 (CD: n = 36 and UC: n = 35) of the 118 IBD patients was available and this subgroup was used to analyze correlations between the individual serum biomarkers and clinical (HBI/SCCAI), biochemical (CRP, fecal calprotectin) and endoscopic (CD: SES-CD score, UC: Mayo score, IBD: composite endoscopy score) measures of disease activity using Spearman’s rank correlation coefficients (ρ). Baseline demographic and clinical characteristics of this subset of patients (n = 71) are presented in Supplementary Table S3. Correlations between serum biomarkers and measures of disease activity are presented in a correlation matrix (Table 2). The SES-CD score positively correlated with serum amyloid A (SAA) (ρ = 0.410, P < 0.05), closely followed by IFN-γ (ρ = 0.383, P < 0.05), IL-8 (ρ = 0.359, P < 0.05) and IL-17A (ρ = 0.352, P < 0.05), while the Mayo endoscopic subscore (for UC) correlated only significantly with serum levels of IL-6 (ρ = 0.356, P < 0.05). An IBD composite endoscopy score was created by merging both endoscopy scores of CD (SES-CD) and UC (Mayo) on categorical level of disease activity (0, 1, 2 or 3). Using this composite IBD endoscopy score (see Supplementary Table S2; n = 71), significant correlations were observed for Eotaxin-1 (ρ = 0.316, P < 0.01), IL-8 (ρ = 0.295, P < 0.05) and SAA (ρ = 0.288, P < 0.05) (Supplementary Figure S1). Furthermore, routinely-measured CRP levels (mg/l) correlated significantly with multiple biomarkers analyzed by the ECL multiplex assay (CRP, SAA, IL-6, IFN-γ and TNF-α). In contrast, fecal calprotectin (FC) levels (n = 25) did not show significant correlations with any of the detected inflammatory biomarkers. Similarly, clinical disease indices only showed a significant correlation with serum IL-6 levels (ρ = 0.349, P < 0.01), whereas the remaining inflammatory biomarkers did not correlate with either HBI or SCCAI scores. Table 2 | Correlations between serum levels of individual biomarkers with endoscopic (SES-CD, Mayo score and composite IBD endoscopy score), biochemical (CRP and fecal calprotectin, FC) and clinical (HBI or SCCAI) measures of disease activity. Correlation matrix showing Spearman’s rank correlation coefficients (ρ) for associations between all detected molecules and clinical, biochemical and endoscopic measures of disease activity. *P-values < 0.05 were considered statistically significant. **P < 0.01. Chapter 8 Table 2. Correlations between serum levels of individual biomarkers with endoscopic (SESCD, Mayo score and composite IBD endoscopy score), biochemical (CRP and fecal calprotectin, FC) and clinical (HBI or SCCAI) measures of disease activity. SES-CD (n = 36) Mayo (n = 35) Composite (n =71) HBI/SCCAI (n = 56) CRP (n = 113) FC (n = 25) CRP (mg/l) 0.155 -0.053 -0.067 0.101 0.871** 0.022 SAA (mg/l) 0.410* 0.208 0.288* 0.006 0.605** 0.064 IFN-γ (pg/ml) 0.383* 0.119 0.048 0.034 0.325** -0.221 TNF-α (pg/ml) 0.021 0.183 0.175 -0.048 0.298** -0.089 IL-6 (pg/ml) 0.164 0.356* 0.129 0.349** 0.450** 0.079 IL-8 (pg/ml) 0.359* 0.118 0.295* -0.076 0.002 0.006 IL-10 (pg/ml) 0.097 -0.023 0.127 0.172 -0.020 0.189 IL-17A (pg/ml) 0.352* -0.073 0.202 -0.125 0.185 0.113 Eotaxin-1 (ng/ml) 0.212 0.144 0.316** 0.060 -0.121 0.053 Eotaxin-3 (pg/ml) -0.205 -0.217 -0,110 -0.059 -0.098 0.028 Correlation matrix showing Spearman’s rank correlation coefficients (ρ) for associations between all detected molecules and clinical, biochemical and endoscopic measures of disease activity. *P-values < 0.05 were considered statistically significant. **P < 0.01.
RkJQdWJsaXNoZXIy MjY0ODMw